Companies Vistagen Therapeutics, Inc.
Vistagen Therapeutics (VTGN): executive pay, fiscal 2026
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Vistagen Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,477,682FY2025
- $1,212,560FY2026
CEO total pay was $1,212,560 in fiscal 2026, down from $2,477,682 in fiscal 2025.
FY2026: salary $650,000 · bonus $0 · stock awards $0 · option awards $562,560
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Shawn Singh | $650,000 | $0 | $0 | $562,560 | $0 | $0 | $0 | $1,212,560 |
| President, Chief Executive Officer and Director | ||||||||
| Nick Tressler | 150,000 | 50,000 | 0 | 641,790 | 0 | 0 | 24,726 | 866,516 |
| Chief Financial Officer and Treasurer | ||||||||
| Elissa Cote | 320,682 | 35,000 | 0 | 281,925 | 0 | 0 | 58,527 | 696,134 |
| Chief Corporate Development and Strategy Officer | ||||||||
| Reid Adler | 450,000 | 0 | 0 | 187,520 | 0 | 0 | 0 | 637,520 |
| Chief Legal Officer | ||||||||
| Joshua Prince | 415,000 | 0 | 0 | 187,520 | 0 | 0 | 0 | 602,520 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Shawn Singh | $1,212,560 | $2,477,682 | — | ↓ −1,265,122 |
| Nick Tressler | 866,516 | — | — | — |
| Elissa Cote | 696,134 | — | — | — |
| Reid Adler | 637,520 | 1,175,807 | — | ↓ −538,287 |
| Joshua Prince | 602,520 | 1,058,250 | — | ↓ −455,730 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation philosophy is designed to attract, retain, motivate and reward NEOs for their performance and contribution to operations and long-term success. It utilizes a mix of cash awarded upon achievement of corporate-wide and individual performance objectives, and retention-focused equity incentives to align NEO incentives with stockholder value creation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2026
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Reid Adler | Option | 276 | 38.4 | — |
| Joshua Prince | Option | 832 | 4.44 | — |
| Joshua Prince | Option | 62,500 | 3.23 | — |
| Reid Adler | Option | 70,833 | 3.23 | — |
| Reid Adler | Option | 75,000 | 1.96 | — |
| Joshua Prince | Option | 75,000 | 1.96 | — |
| Elissa Cote | Option | 150,000 | 1.96 | — |
| Nick Tressler | Option | 150,000 | 4.43 | — |
| Shawn Singh | Option | 208,333 | 3.23 | — |
| Shawn Singh | Option | 225,000 | 1.96 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Margaret M. FitzPatrickIndependent · Compensation Committee · Not standing for re-election | $92,500 | — | $59,197 | — | $0 | $151,697 |
| Paul R. EdickIndependent · Audit · Departed during FY | 20,145 | — | 131,187 | — | 0 | 151,332 |
| Jon S. SaxeIndependent · Audit Committee (Chair) · Compensation Committee · Corporate Governance and Nominating Committee | 75,000 | — | 59,197 | — | 0 | 134,197 |
| Mary L. RotunnoIndependent · Audit · Corporate Governance and Nominating (Chair) · Departed during FY | 70,000 | — | 59,197 | — | 0 | 129,197 |
| Joanne CurleyIndependent · Audit Committee · Corporate Governance and Nominating Committee · Not standing for re-election | 60,000 | — | 59,197 | — | 0 | 119,197 |
| Ann M. CunninghamIndependent · Audit Committee · Compensation Committee (Chair) · Corporate Governance and Nominating Committee (Chair) | 50,000 | — | 59,197 | — | 0 | 109,197 |
| Jerry B. GinIndependent · Audit · Compensation (Chair) · Departed during FY | 35,000 | — | 0 | — | 0 | 35,000 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 10,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2026 |
|---|---|
| Cash retainers and fees | $402,645 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $402,645 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Vistagen Therapeutics as a peer
Companies that benchmark against VTGN
- ORAMED PHARMACEUTICALS INC.ORMPFY2024
Each company listed discloses VTGN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Vistagen Therapeutics, Inc. | 2026 | Shawn Singh | $650,000 | $0 | $562,560 | $0 | $1,212,560 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (15 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Shawn Singh. DEF 14A, filed 2026-07-31. Section “Executive Compensation”. As printed: 1,212,560. View filing ↗
- Section 01, Nick Tressler. DEF 14A, filed 2026-07-31. Section “Executive Compensation”. As printed: 866,516. View filing ↗
- Section 01, Elissa Cote. DEF 14A, filed 2026-07-31. Section “Executive Compensation”. As printed: 696,134. View filing ↗
- Section 01, Reid Adler. DEF 14A, filed 2026-07-31. Section “Executive Compensation”. As printed: 637,520. View filing ↗
- Section 01, Joshua Prince. DEF 14A, filed 2026-07-31. Section “Executive Compensation”. As printed: 602,520. View filing ↗
- Section 08, Margaret M. FitzPatrick. DEF 14A, filed 2026-07-31. Section “Director Compensation”. As printed: 151,697. View filing ↗
- Section 08, Paul R. Edick. DEF 14A, filed 2026-07-31. Section “Director Compensation”. As printed: 151,332. View filing ↗
- Section 08, Jon S. Saxe. DEF 14A, filed 2026-07-31. Section “Director Compensation”. As printed: 134,197. View filing ↗
- Section 08, Mary L. Rotunno. DEF 14A, filed 2026-07-31. Section “Director Compensation”. As printed: 129,197. View filing ↗
- Section 08, Joanne Curley. DEF 14A, filed 2026-07-31. Section “Director Compensation”. As printed: 119,197. View filing ↗
- Section 08, Ann M. Cunningham. DEF 14A, filed 2026-07-31. Section “Director Compensation”. As printed: 109,197. View filing ↗
- Section 08, Jerry B. Gin. DEF 14A, filed 2026-07-31. Section “Director Compensation”. As printed: 35,000. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 402,645 + equity 0 + all other 0 = 402,645, summed across the director compensation table rows.
- Vistagen Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-07-31. CEO total compensation as printed in Vistagen Therapeutics, Inc.'s own proxy. As printed: 1,212,560. View filing ↗